Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (5): 797-801    DOI: 10.31083/j.ejgo.2020.05.2086
Case Report Previous articles | Next articles
Neoadjuvant chemotherapy, radical hysterectomy and chemoradiation for stage iva cervical carcinoma
John P. Micha1, Howard D. Epstein2, Michael C. Roossin3, Randy Bohart4, Mark A. Rettenmaier5, Bram H. Goldstein6, *()
1Gynecologic Oncology Associates Partners, 361 Hospital Road, Suite #422, Newport Beach, CA 92663, USA
2Department of Pathology, Hoag Hospital, 361 Hospital Road, Newport Beach, CA 92663, USA
3Department of Radiology, Hoag Hospital, 361 Hospital Road, Newport Beach, CA 92663, USA
4Oso Home Care, 17175 Gillette Ave, Irvine, CA 92614, USA
5351 Hospital Road, Suite #506, Newport Beach, CA 92663, USA
6Women's Cancer Research Foundation, Newport Beach, CA 92663, USA
Download:  PDF(686KB)  ( 152 ) Full text   ( 11 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Despite the efficacy of chemotherapy and radiotherapy in the management of locally advanced cervical carcinoma, the overall survival rates are relatively inauspicious. We recount a case involving a 56-year-old stage IVA cervical cancer patient who underwent neoadjuvant chemotherapy, a type V radical hysterectomy and adjuvant chemoradiation in April 2006. The patient remained in clinical remission for five years until she developed a metastatic pulmonary nodule in her right middle lobe that originated from the primary cervical cancer. Thereafter, the patient was diagnosed with a right metastatic cardiophrenic nodule that responded favorably to chemotherapy. However, in August 2014, she presented with a metastatic posterior cranial fossa tumor from which she ultimately expired; interestingly, radiologic imaging revealed no evidence of an abdominopelvic recurrence. While a radical hysterectomy is often indicated for advanced cervical cancer patients with residual disease or those who fail chemoradiation, perhaps in select cases (e.g., stage IVA disease), initial treatment with neoadjuvant chemotherapy and surgery followed by chemoradiation may improve patient survival.
Key words:  Cervical cancer      Radical hysterectomy      Chemoradiation      Outcomes     
Submitted:  23 October 2019      Accepted:  04 June 2020      Published:  15 October 2020     
*Corresponding Author(s):  BRAM GOLDSTEIN     E-mail:  bram@gynoncology.com

Cite this article: 

John P. Micha, Howard D. Epstein, Michael C. Roossin, Randy Bohart, Mark A. Rettenmaier, Bram H. Goldstein. Neoadjuvant chemotherapy, radical hysterectomy and chemoradiation for stage iva cervical carcinoma. European Journal of Gynaecological Oncology, 2020, 41(5): 797-801.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.05.2086     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I5/797

[1] Eda Kucuktulu, Ahmet Fatih Yurekli. Simultaneous Integrated Intensity Modulated Radiotherapy Boost for Gynecological Cancer when Brachytherapy is not an Option[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 720-725.
[2] Wook Youn Kim, Shin Hee Seo, Seung-Hyuk Shim, Jin Hee Park, Hyung Kyu Park, Kyeong A So, Tae Jin Kim, Sun Joo Lee. Correlation of immunohistochemistry and silver in situ hybridization for the assessment of c-MET in uterine cervical cancer patients treated with radical hysterectomy[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 745-752.
[3] Juan Xu, Qingqing Tan, Ting Li. USP22 promotes the expression of GLUT1 and HK2 to facilitate growth and glycolysis in cervical cancer cells[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 790-796.
[4] Yan qin Zhang, Di Wu, Meng qi Deng, Xiang yu Chang, Jin wei Miao, Yu mei Wu. Individual management of cervical cancer during pregnancy[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 833-837.
[5] Yi-fan Luo, Li-xiang Ren, Ming-yan Jiang, Yang Chu. A systematic review and meta-analysis on the effects of metformin on survival outcomes and risk in women with cervical cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 504-507.
[6] Liman Yang, Jing Jin, Juhong Liu. Correlation of MMP2-C1306T (rs243865) and MMP7-181A/G (rs11568818) with cervical cancer: a meta-analysis[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 508-512.
[7] Sun Yi Choe, Jung-Woo Park. Prognostic significance of the number of metastatic lymph nodes in early cervical cancer: a retrospective study[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 536-540.
[8] Panteleimon Mnimatidis, Abraham Pouliakis, George Valasoulis, George Michail, Aris Spathis, Christine Cottaridi, Niki Margari, Maria Kyrgiou, Maria Nasioutziki, Alexandros Daponte, Konstantinos Dinas, Evangelos Paraskevaidis, Ioannis Panayiotides, Dimitrios-Dionysios Koutsouris. Multicentric assessment of cervical HPV infection co-factors in a large cohort of Greek women[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 545-555.
[9] Krittiya Somaketarin, Charuwan Tantipalakorn, Kittipat Charoenkwan, Prapaporn Suprasert, Jatupol Srisomboon. Survival outcomes of sex cord-stromal tumors of the ovary[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 563-568.
[10] Fengmei Wang , Huachun Luo , Huihua Cheng, Huijuan Huang , Zhichao Fu. Is 3D printing-gided three-dimensional brachytherapy suitable for cervical cancer: from one single research institute?[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 591-597.
[11] Hiroshi Yoshida, Megumi Yamamoto, Hiroyuki Shigeta. Successful treatment of uterine cervical carcinoma with extensive vaginal lesions using laparoscopic surgery: A case report[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 629-633.
[12] Hikari Unno, Seiji Mabuchi, Isao Arai, Tomoko Wakasa, Seiichi Yamamasu. Development of lymphangiosarcoma after pelvic radiation therapy for uterine cervical cancer: A case report and literature review[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 326-331.
[13] X. Zhang, Y. Fu, X. Zhang, J. Ding, K. Hua. The effect of transcutaneous electrical stimulation treatment in combination with intraoperative nerve staining on sexual function after radical hysterectomy: a pilot study[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 188-191.
[14] L. Xu, H. Cai, N. Zhu, Bo Zheng. Interleukin-22 derived from cervical cancer-associated fibroblasts accelerates senescence of normal fibroblasts and promotes expression of tumorigenesis-related factors in HeLa cells[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 192-199.
[15] Hong Yan, Chunhua Zhang, Tingting Liu, Jianzhong Liu. Mifepristone regulates the multidrug resistance via miR-758/MEPE of Hela cell lines[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 214-220.
[1] Eli M. Roth, Michael H. Davidson. PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety[J]. Reviews in Cardiovascular Medicine, 2018, 19(S1): 31 -46 .
[2] B. Soltész, J. Lukács, A. Penyige, R. Póka, B. Nagy. Determination of miR-193b rs30236 single nucleotide polymorphism in ovarian cancer patients[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 547 -550 .
[3] Y. Li, C. Li, N. Li, L. Jiang, W. Yang, Y. Wang, B. Wu, C. Shi, Z. Zhu. RNAi silenced NUP88 gene suppresses growth and invasiveness of human breast cancer cell line MCF-7[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 634 -639 .
[4] M. Pakiž, L. Lukman, N. Kozar. Patients' and physicians' expectations differ significantly during the follow-up period after completion of primary treatment of gynecological or breast cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 781 -786 .
[5] T. Tomimatsu, S. Mabuchi, T. Tsuboyama, Y. Hori, S. Sekine, T. Kimura. Malignant transformation of uterine leiomyoma: suggested by clinical, imaging, histological, and genetic findings[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 879 -882 .
[6] Z. Protrka, P. Arsenijevic, N. Jovic, S. Zivanovic, J. Djuric, A. Dimitrijevic. A case of uterine torsion in term pregnancy associated with placental abruption and intrauterine fetal demise[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(2): 287 -289 .
[7] T. Ueno, H. Yabushita, K. Iwasaki, A. Wakatsuki. Role of adiponectin and leptin in non-diabetic, non-obese patients with endometrial cancer[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 199 -204 .
[8] P. Pimsi, W. Santimaleeworagun, S. Therasakvichya, N. Saengsukkasemsak, A. Laocharoenkeat. The incidence and risk factors of severe neutropenia and febrile neutropenia due to chemotherapy among gynecologic cancer patients in Thailand[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 242 -246 .
[9] F. Lai-Tiong. Dermatomyositis revealing a 18-year breast cancer recurrence[J]. European Journal of Gynaecological Oncology, 2018, 39(2): 292 -293 .
[10] M.F. Benoit, K.A. O'Hanlan, M.S. Sten, C.L. Kosnik, D.M. Struck, M.S. O'Holleran, J. Cuff, D.M. Halliday, E.A. Kent. Incidental appendectomy at the time of gynecologic surgery[J]. European Journal of Gynaecological Oncology, 2018, 39(3): 386 -389 .